Tempest Therapeutics announced positive interim results from its Phase 1/2a trial of TPST-2003, a dual-targeting CAR-T therapy for relapsed/refractory multiple myeloma, showing a 100% complete response rate among evaluable patients and a favorable safety profile. The company completed a strategic acquisition of CAR-T assets from Factor Bioscience, strengthening its pipeline. Tempest plans to initiate a US registrational study for TPST-2003 later in 2026 and advance other therapies, including amezalpat and TPST-1495, with ongoing clinical and regulatory progress. Financially, Tempest ended 2025 with $7.7 million in cash and reduced net loss compared to 2024, reflecting focused R&D spending and strategic funding efforts.
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
Red Light Holland, after acquiring Filament Health, has expanded its capabilities in pharmaceutical-grade psilocybin development. Filament completed a shipment of its botanical psilocybin drug candidate, PEX010, to the European Union to support multi...
Wendy's is running a $1 promotion on small Classic Chocolate or Vanilla Frosty from July 20 to August 23, with early access for Wendy's Rewards members on July 19 in celebration of National Ice Cream Day. The offer is redeemable via the Wendy's app a...
Inseego Corp. will release its financial results for the second quarter of 2026 on August 5, after market close. The company will hold a conference call the same day to discuss the results and business outlook. Investors can access the earnings repor...
Dyadic International has expanded its bio-industrial pipeline with a new proprietary enzyme program focused on advanced cellulose processing, building on the success of its EN3ZYME™ product. This initiative leverages Dyadic's Dapibus™ platform to str...
